

## Poster Presentations

### Acute

001 An unusual cause of lymphocytic meningitis: Anna Alexandratou

002 Neuromyelitis optica or HIV: the chameleon strikes again?: William Clark

003 A case of SARS-CoV-2 Omicron variant associated acute encephalomyelitis: Michelle Olivia Dsouza

004 Dermato myo myelitis: a case of concurrent anti-synthetase syndrome and NMOSD: Simon Heller

005 A case of xanthomatous hypophysitis presenting as recurrent pituitary adenoma: Kabir Khan Nazeer

006 A novel approach in the management of functional neurological disorder in the hyper-acute setting: Michelle Balaratnam

007 Functional neurological disorders and sociodemographic factors: a review: Micha Vidot

008 Is primary new daily persistent headache de novo chronic migraine and chronic tension-type headache?: Sanjay Cheema

009 Asymmetric peri-optic cerebrospinal fluid space distension in cluster headache: Mena Farag

010 Trigeminal neuralgia in diffuse scleroderma – a rare but recognised association: Jamie Talbot

011 A case of a neurological immune-related adverse event associated with ipilimumab/nivolumab: Josh Walker

012 Neurological signs in a general neurology face to face clinic during the Covid-19 pandemic: Udo Wiesmann

### Quality & training

013 The community neuroscience project: transforming the delivery of neuroscience care across North Central London: Michelle Balaratnam

014 Medical student and consultant surveys assessing educational value of telephone and video neurology clinics: Katharine Balfour

015 Service evaluation: the role of same day emergency care in managing acute neurological presentations: Catherine Hsu

016 Developing a medical in-reach service at a specialist neurosciences centre: a quality improvement initiative: Naveen Kumar

017 The evolution of neurological admissions preceding and during the Covid-19 pandemic: Prisca Singh

018 Neurology virtual clinic: quality improvement project: Kyriakoula Varpompiti

019 A retrospective analysis of shunts for idiopathic intracranial hypertension: A 10-year experience at St. George's University Hospital: Sathyajith Buddhika Ambawatte

020 The national headache management system: a route to ensuring nationwide evidence based and equitable care: Alex Gordon

021 The Headache Hub: a multidisciplinary diagnosis and management resource for GPs: Anne-Marie Logan

022 Experience from a SARS-CoV2 neurology clinic at the National Hospital of Neurology and Neurosurgery: Simeona Jacinto

023 Preliminary results from a consultant-led acute neurology service based in the emergency department: Ali Alim-Marvasti

024 Impact of pandemic on neurologists and neurology practice: Christopher Kipps

025 Quality improvement in acute neurology- tales from same day emergency care: Richard Nicholas

026 Croydon neurology: assessing the impact of the introduction of patient initiated follow-up: Arani Nitkunan

027 Croydon neurology: 5 years of novel service developments: Fred Schon

028 Croydon neurology: Our DGH specialist nurse delivered lumbar puncture (LP) service: Fred Schon

029 Patient reported experience of acute neurology telephone clinics during COVID-19 pandemic: Kit Wu

030 Croydon neurology: diagnostic coding of outpatients – the first year of experience: Arani Nitkunan

### Autonomic, neuro-oncology and neurogenetic

031 Botulinum toxin injections into the urethral sphincter for managing urinary retention in Fowler's syndrome: Piriyanakan Ananthavarathan

032 Post COVID-19 syndrome dysautonomia: a tertiary referral centre experience: Sean Apap Mangion

033 Pelvic autonomic dysfunction is common in patients with pure autonomic failure: Ekawat Vichayanrat

034 Supine hypertension and cardiovascular autonomic failure in patients with alpha-synucleinopathies: Ekawat Vichayanrat

035 Extracranial-tumor cerebri: Simon Heller

036 Revolutionary cancer treatment: a pyrrhic victory?: Iman Saeed

037 Brain tumours and sociodemographic factors: a review: Micha Vidot

038 A GWAS of LGI1-antibody encephalitis: Sophie Binks

039 Apparent homozygous c.830G>A GNE myopathy in non-jewish Iraqi: Nicholas Keyi Sim

040 Cerebellar cognitive affective syndrome in ataxia-telangiectasia patients: May Yung Tiet

## Poster Presentations - Continued

041 Solriamfetol real world experience study (SURWEY): safety and effectiveness for patients with narcolepsy from Germany: Daniela Girfoglio

042 Diagnosing primary brain tumours: a retrospective audit at the Queen Elizabeth Hospital, Birmingham: Tom Hayton

### Cognitive

043 Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis: Michael David

044 Longitudinal assessment of sleep/wake behaviour in dementia patients living at home: Magdalena Kolanko

045 Depression is associated with increased dementia risk and reduced grey matter in a fronto-insular-cerebellar network: Alvar Paris

046 At what resolution does the brain perform computations?: Aneirin Potter

047 Survival in frontotemporal lobar degeneration: identifying blood, brain and behavioural predictors of survival : Katherine Stockton

048 Sporadic Creutzfeldt-Jakob disease in the young: a 10 year review of United Kingdom national surveillance: Johnny Tam

049 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series : Neil Watson

050 Impact of the COVID-19 pandemic on Creutzfeldt-Jakob disease surveillance and patient care in the UK: Neil Watson

051 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer's disease: Ruth Wood

052 Feasibility of an automated assessment to measure cognition and mood in the acute stroke setting: Daniel Blackburn

053 Stakeholder opinions of telematics as an alternative assessment for MCI drivers; a thematic analysis: Daniel Blackburn

054 SKYLINE study design: efficacy and safety of gantenerumab in participants at-risk for Alzheimer's disease: Sofia Bullcain

055 Brainshuttle AD: investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD: Luka Kulic

056 Baseline characteristics of the Phase III GRADUATE studies: investigating subcutaneous gantenerumab in early AD: Christopher Lane

057 Assessment of MACE cognitive screener using efficiency indexes: Andrew Larner

058 Online assessment and monitoring of cognitive decline in neurological conditions: Annalaura Lerede

059 Dementia and sociodemographic factors: a review: Kit Wu

### Epilepsy

060 Does prolonging duration of monitoring in epilepsy monitoring unit improve diagnostic yield?: Mohammad Hijaz Adenan

061 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?: Smriti Bose

062 LFT monitoring for patients prescribed cannabidiol - an audit of current practice at QEH - Birmingham: Mohammed Elkider

063 The long-term effects of anterior temporal lobe resection on memory encoding: a longitudinal fMRI study: Marine Fleury

064 Ictal asystole during a generalised seizure following a photoparoxysmal response: Michael Gilligan

065 The role of monoclonal antibodies in contrasting cases of NORSE: Tom Lightning

066 Epilepsy and sociodemographic factors: a review: James Mitchell

067 Septal DNETs rarely cause seizures - consider other causes: Matthew Tanti

068 The utility of 18-FDG PET imaging in the preoperative workup for epilepsy surgery: Sarah Wrigley

069 One Health: clinical characteristics of spontaneously-arising feline LGII-autoantibody limbic encephalitis in a large international cohort: Sophie Binks

070 Effect of low dose adjunctive perampanel in adults and adolescents with focal-onset seizures: Samantha Goldman

071 Real-world evidence on the safety and efficacy of adjunctive perampanel across different geographical regions: Leock Y Ngo

072 Real-world experience of perampanel monotherapy in epilepsy patients with focal-onset and generalised-onset seizures: Leock Y Ngo

073 Perampanel as early add-on therapy for focal-onset and generalised-onset seizures in clinical practice: Estevo Santamarina

074 Fenfluramine directly inhibits cortical spreading depolarisation: a pathophysiological process linked to SUDEP: Zhen Tan

075 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome: Zhen Tan

076 No valvular heart disease or pulmonary artery hypertension with fenfluramine for up to 3 years: Zhen Tan

### Headache

077 Anxiety and depression in women with idiopathic intracranial hypertension: a matched controlled retrospective cohort study : Matilde Sasani

078 Iatrogenic spinal haematoma post lumbar puncture: a case report and literature review: Matilde Sasani

## Poster Presentations - Continued

079 Opiate and headache prescribing patterns in idiopathic intracranial hypertension: a matched controlled retrospective cohort study: Matilde Sasani

080 Bruns syndrome - broadening the phenotype: Arshia Seddigh

081 Does the timing of IIH diagnosis in relation to pregnancy affect outcomes?: Mark Thaller

082 IIH Life: a prospective longitudinal cohort study of idiopathic intracranial hypertension: Mark Thaller

083 Impact of co-morbid PCOS on IIH outcomes: Mark Thaller

084 Obstructive sleep apnoea in idiopathic intracranial hypertension: a sub-study of the IIH-WT randomised controlled trial: Andreas Yiangou

085 Intravenous magnesium for acute presentations of migraine to A&E: Raphael Laurente

086 Migraine and sociodemographic factors: a review: James W Mitchell

087 Medication overuse reversion following fremanezumab treatment in migraine patients with inadequate response to prior preventives: Lydia Blume

088 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes: Dalbir Dhiraj

089 A rarity of a rare condition - do we have a HaNDL on it?: Seema Kalra

090 Croydon neurology: assessing the use of a new headache pathway and referral form: Arani Nitkunan

091 Re-admission rate for patients with headache in Southwest London – can this be addressed?: Arani Nitkunan

092 Frequency of migraine and the use of preventive medication in a UK primary care population: Andrew Pain

### Movement disorders

093 The East London Parkinson's disease project - engaging a diverse population in research: Aaron Ben-Joseph

094 Brain amylin accumulation in Parkinson's disease is not driven by type 2 diabetes mellitus: Patrick Cullinane

095 Screening of non-motor symptoms of Parkinson's disease and dementia with Lewy bodies: clinical audit: Rowan Gurney

096 Dual target deep brain stimulation for clinically complex tremor disorders: a single centre prospective study: Rosie Heartshorne

097 Diffusion magnetic resonance imaging in dystonia: a review of methodological approaches and findings: Claire MacIver

098 Artificial intelligence based detection of Parkinson's disease in magnetic resonance imaging brain scans: Stephen Mullin

099 Motor and non-motor features of prodromal Parkinson's in idiopathic anosmia: Richard Rees

100 Transcranial sonography in the prodromal phase of PD: Richard Rees

101 Neuroimaging correlates of cognitive deficits in Wilson's disease: Samuel Shribman

102 The prevalence of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) in Scotland: Diane Swallow

103 Thrombotic and haemorrhagic complications associated with PLEX, reducing the risks: Nicole Japzon

104 Antiphospholipid-related chorea: Mena Farag

105 Motor and non-motor features of prodromal PD: Richard Rees

106 Levodopa and melanoma: what do clinicians think?: Alex Symonds

107 A novel MRI biomarker for ataxia-telangiectasia: evaluating the lack of hypointensity of the dentate nuclei: May Yung Tiet

108 Defining the neuronal phenotype in a human cell model of DYT1 dystonia: Sarah Wrigley

109 Examining the sex differences in the prevalence and incidence of Parkinson disease: Alexandra Zirra

110 A rare presentation of Bickerstaff's brainstem encephalitis: Robyn Stansfield

111 Critical ischaemia without infarction presenting as progressive hemichorea: a case study and literature review: Sarah Wrigley

112 Short term neuropsychiatric outcomes of STN – DBS using directional vs conventional ring mode stimulation: Sundus Alusi

113 An analysis of specialist services for Huntington's disease in the UK: Rachel Blair

114 Embedding patient voice in trial design: the EJS ACT-PD experience: Camille Carroll

115 Outcome and mortality of hospital admission with COVID-19 for individuals with parkinsonian syndromes: Camille Carroll

116 Factors that affect care needs in people with Parkinson's disease: a patient perspective: Christopher Kipps

117 Parkinson's disease and sociodemographic factors: a review: Kit Wu

### MS

118 Assessing predictors of NEDA in RRMS patients initiating dimethyl fumarate in a real-world setting: Sarmad Al-Araji

119 Pain and objectively measured cognitive performance in adults with multiple sclerosis: a systematic review: Fraser Brown

## Poster Presentations - Continued

120 Treatment of non-HIV progressive multifocal leukoencephalopathy with pembrolizumab: a single-centre case series: Thomas Cox

121 Evaluating the introduction of subcutaneous natalizumab to a cohort of patients with multiple sclerosis: Marc Edwards

122 Who is the culprit - the virus or the anti-virus?: Mohammed Elkider

123 Acute disseminated encephalomyelitis associated with SARS-CoV-2 vaccine in multiple sclerosis: a case report: Matthew Evans

124 A novel kinematic tool to assess upper limb dysfunction in multiple sclerosis: Linford Fernandes

125 UK multiple sclerosis registries project: disease modifying treatment durability: Joseph Froud

126 Polyarteritis nodosa presenting with posterior reversible encephalopathy syndrome: Rosie Heartshorne

127 The ADAMS project: Protocol and baseline results: Benjamin Jacobs

128 A case of posterior reversible encephalopathy syndrome: A rheumatologic conundrum: Zanaib Mahmud

129 Oxidative stress responses - potential biomarkers in multiple sclerosis: Thomas Minton

130 Multiple sclerosis and sociodemographic factors: a review: James Mitchell

131 Real world data evaluating efficacy and safety of oral cladribine for multiple sclerosis: Moneeb Nasir

132 Hepatitis B serological screening in people with multiple sclerosis treated with disease modifying treatments: Timothy Prossor

133 The provision of anti-CD20 therapy in inflammatory demyelinating disorders of the CNS during SARS-CoV-2: Imogen Smedley

134 Effect of reduced blood monitoring frequency in patients on dimethyl fumarate during the COVID-19 pandemic: David Vaughan

135 Visuoperceptual deficits as measures of cognitive dysfunction in multiple sclerosis: a pilot study: Victoria Whitford

136 A digital resilience-training programme to improve job retention in MS: A multicentre pilot trial: Charli Wicks

137 Multiple sclerosis relapse patterns in a population-based cohort: Ray Wynford-Thomas

138 IgLON5-antibody disease: a case series: Nick Yapp

139 The impact of the COVID-19 pandemic on MS services in the UK: a multicentre survey: Tarunya Arun

140 Understanding the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis: Luke Ashton

141 Adverse prognostic factors predicting disease modifying therapies in MS: a real-world cohort: Marija Cauchi

142 Multiple sclerosis and the risk of infection: a consensus guideline: Marija Cauchi

143 Predictors of serum vitamin D level in multiple sclerosis: Ruth Dobson

144 The UK MS pregnancy register: Baseline data from the first fifty enrolled patients: Ruth Dobson

145 NOVA primary results: randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS: Gavin Giovannoni

146 Impact of absolute lymphocyte count (ALC) frequency on detection of dimethyl fumarate-associated lymphopenia: Shooka Hadipour

147 Done in 16 Seconds: Extracting research ready data from NHS clinical letters: Rod Middleton

148 Characterising DARC (Detecting Apoptosing Retinal Cells) spots in optic neuritis: Richard Nicholas

149 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program: Richard Nicholas

150 Evaluation of the satisfaction and value of Your MS™ questionnaire in supporting patient-healthcare professional consultation: Pritpal Panesar

151 Cognitive processing speed predicts disease progression in SPMS: post hoc analysis from the EXPAND study: Katherine Rhys

152 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment: Katherine Rhys

153 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND: Katherine Rhys

154 Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis: Katherine Rhys

155 Long-term safety of ofatumumab in patients with relapsing multiple sclerosis: Katherine Rhys

156 MRI activity versus relapses as markers of SPMS disease activity: real world and pivotal trials: Katherine Rhys

158 Siponimod preserves retinal thickness: Findings from the EXPAND OCT substudy: Katherine Rhys

159 Treating newly diagnosed relapsing-remitting multiple sclerosis (RRMS): a 2021 clinician survey in the United Kingdom: Katherine Rhys

160 Down but not out, repurposing depression treatments for multiple sclerosis with the UK MS Register: William Rodgers

161 The 70 UK centre multiple sclerosis service and DMT prescribing audit: practical project solutions: David Rog

162 Updated analysis of pregnancy outcomes for patients with MS in a dimethyl fumarate exposure registry: David Rog

## Poster Presentations - Continued

163 AttackMS: natalizumab for the treatment of people with inflammatory demyelination suggestive of multiple sclerosis: Klaus Schmierer

164 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS): Klaus Schmierer

165 Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate: Emma Tallantyre

166 Reasons for stopping MS disease modifying treatment in a UK cohort: Emma Tallantyre

167 Association of locus of control with clinical and psychosocial aspects of living with multiple sclerosis: Carolyn Young

168 Natalizumab treatment satisfaction in the TONIC-MS study: study design: Carolyn Young

169 Natalizumab treatment satisfaction in TONIC-MS study: preliminary results from i.v. participants on infusion experience: Carolyn Young

### TBI & other

170 The growing role of the neuropharmacist: helping to deal with staff shortages in other professions: Joela Mathews

171 Ophthalmological involvement in m.3243A>G-related mitochondrial disease: Helen Devine

172 Recurrent painful ophthalmoplegic neuropathy vs oculomotor schwannoma: Arshia Seddigh

173 Use of brain imaging and EEG for prognostication in post-cardiac arrest coma: Charles Carey

174 Immunosuppression guidelines: Ongoing implementation project: Nicole Japzon

175 The role of MEG in assessment and diagnosis in mTBI: Christopher Allen

176 The advanced BRAIN health clinic and study of long-term neurological outcomes in retired elite athletes: Neil Graham

177 Exploring interactions between traumatic brain injury and cognitive co-morbidity: descriptive case analysis from real-world monitoring: Lucia Li

178 mTBI Predict: A prospective biomarker study to predict outcomes in mild traumatic brain injury: Hannah Lyons

179 Traumatic brain injury and sociodemographic factors: a review: Micha Vidot

180 An audit into the management of functional neurological disorder in Salford: James Houston

181 Placebo – to use or not to use? Survey on the use of placebo treatments: Anne-Catherine Huys

### MND/SMA

182 Commencing novel therapies for adult SMA patients: experience from a hybrid clinic: Zahra Cader

183 Urinary P75: a novel biomarker for motor neuron disease?: Laura Chapman

184 Impact of age on interventions and survival in people with motor neuron disease in Scotland: Alexander Christides

185 Transcriptional phenotypes of a human stem cell model of Spinal Bulbar Muscular Atrophy (SBMA): Helen Devine

186 A novel proposed panel of inflammatory and redox genes as biomarkers in amyotrophic lateral sclerosis: Ilaria Giovannelli

187 Croydon neurology: audit of the site of death of patients with motor neurone disease: Meneka Kanagaratnam

188 A case series of anti-HMGCR immune mediated necrotising myopathy: The West Midlands data: Pyae Phyo San

189 Motor fatigability in motor neuron disease: Matilde Sasani

190 An unusual presentation in motor neurone disease: Robyn Stansfield

191 Motor neurone disease and sociodemographic factors: a review: Micha Vidot

192 Impact inventory development in neurological pathways: Christopher Kipps

193 NeuroHealth: designing a well-being app for people with neuroscience conditions using co-production principles: Kit Wu

194 The diagnostic crisis in mTBI – proposal of a novel neurovascular approach: Abhijit Das

195 Pooled safety data from the risdiplam clinical development programme: Giovanni Baranello

196 Lumbar ports to deliver nusinersen in SMA: First adult and paediatric patients in the UK: Channa Hewamadduma

198 ROADS to remote monitoring of ALS: Malcolm Proudfoot

199 JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with SMA receiving risdiplam: Mariacristina Scoto

200 Risdiplam through the UK early access to medicines scheme for patients with spinal muscular atrophy: Mariacristina Scoto

201 SUNFISH Part 2: 24-month efficacy of risdiplam compared with external control comparators: Laurent Servais

202 SUNFISH: 3-year efficacy and safety of risdiplam in types 2 and 3 SMA: Laurent Servais

## Poster Presentations - Continued

### PN/SMA

- 204 Real world experience on use of rituximab at regional refractory myasthenia gravis clinic in Birmingham: Pyae Phyo San
- 205 Nusinersen treatment in adults with spinal-muscular-atrophy with complex-spinal anatomy at St. George's Hospital, London: Sathyajith Buddhika Ambawatte
- 206 Real world treatment with risdiplam in adults with type-2 spinal muscular atrophy at St George's Hospital, London: Sathyajith Buddhika Ambawatte
- 207 Tacrolimus-induced chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a case series: Matthew Evans
- 208 Unusual presentation of hereditary neuropathy with liability to pressure palsies (HNPP): Eng Chuan Foo
- 209 CANVAS-related sensory ganglionopathy without severe ataxia - the importance of muscle afferents in proprioception: Mary Clare McKenna
- 210 Management of optic disc swelling in atypical inflammatory neuropathy: Trisha Mukherjee
- 211 A segmental enigma: Thinking around the edges: Harri Sivasathiaselan
- 212 Clinical and molecular characterisation of a Scottish Charcot-Marie-Tooth disease cohort: Taylor Watson-Fargie
- 213 Plasma exchange and immunoadsorption in CIDP - a multicenter retrospective cohort study: Surapi Bhairavi Wijayendran
- 214 Checkpoint inhibitor associated neuritis: a novel pathological entity: Aisling Carr

### Vascular

- 215 Should we thrombolysse cognitively impaired patients with acute ischaemic stroke?: Simon Bell
- 217 Mechanical thrombectomy for acute ischaemic stroke: outcomes from Sheffield: Sophie Moore
- 218 Covid-19 and acute ischaemic strokes in CADASIL: a systematic review of the literature: Yassine Noui
- 219 A case report of Collet Sicard syndrome: Muhammed Ameen Noushad
- 220 Frequency of inter-specialty consensus decisions and adherence to advice following a weekly neurovascular multidisciplinary meeting: Chika Offiah
- 221 A case of post COVID-19 endotheliitis: Timothy Prossor
- 222 Improving access to cardiac monitoring for acute stroke patients: a quality improvement project: Nick Scott
- 223 Relationship between thrombin generation and micro-embolic signals in moderate-severe asymptomatic and symptomatic carotid stenosis patients: Arun Subramanian
- 224 Stroke and sociodemographic factors: a review: Micha Vidot
- 225 Bayesian revolution in stroke research – a four-arm hypothetical study for neuroprotection in the hyperacute stage: Abhijit Das